<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05018221</url>
  </required_header>
  <id_info>
    <org_study_id>BEAT-Calci</org_study_id>
    <nct_id>NCT05018221</nct_id>
  </id_info>
  <brief_title>Better Evidence and Translation for Calciphylaxis</brief_title>
  <acronym>BEAT-Calci</acronym>
  <official_title>Better Evidence and Translation for Calciphylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sydney</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Australasian Kidney Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Salford Royal NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Waitemata District Health Board</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sydney</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This global platform study will evaluate multiple interventions, across several domains of&#xD;
      therapeutic care, in adult patients with kidney failure and newly diagnosed calciphylaxis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BEAT-Calci is a randomized, adaptive, multi-center, platform trial that will evaluate&#xD;
      multiple interventions, across several domains of therapeutic care. The objective of the&#xD;
      study is to establish high-quality evidence on the effect of a range of interventions in&#xD;
      patients with kidney failure and newly diagnosed calciphylaxis. Calciphylaxis is a rare&#xD;
      disease affecting 1-2 people in 10,000.&#xD;
&#xD;
      The trial will commence with a Dialysis Membrane Domain and Pharmacotherapy Domain. The&#xD;
      Pharmacotherapy Domain of BEAT-Calci is a placebo-controlled, double blind, response&#xD;
      adaptive, randomised controlled trial that will investigate whether any of the&#xD;
      pharmacotherapeutic agents is superior to placebo in improving outcomes. The Dialysis&#xD;
      Membrane Domain of BEAT-Calci is an open-label, randomised controlled two-way comparison&#xD;
      between two different dialysis technologies.&#xD;
&#xD;
      The BEAT-Calci Wound Assessment Scale (BCWAS) is the primary endpoint for the trial. It is an&#xD;
      8-point ordinal categorical scale of disease outcomes and will be used to determine each&#xD;
      participant's outcome.&#xD;
&#xD;
      The trial will utilise a Bayesian adaptive sample size re-estimation approach for sample size&#xD;
      calculations. The trial will continue to recruit until predefined superiority or futility&#xD;
      rules are met. As the trial progresses, in response to information accumulating during the&#xD;
      trial, there are various adaptations that can occur, including addition or removal of an&#xD;
      intervention arm, response adaptive randomisation and addition of new therapeutic domains.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2021</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Adaptive, platform, randomized controlled trial, involving multiple interventions spanning several domains of therapeutic care.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Blinding of all parties will not be possible for all domains. The default position of the BEAT-Calci platform is that treatments determined by randomization will be blinded to as high a level is feasible.&#xD;
Within practical domains, a blind will be adopted, whereby participants, site personnel, trial investigators and outcome assessors will remain blinded to the treatment from the time of randomization until database lock of the comparisons to which that participant is contributing data. In blinded domains, randomization data will not be accessible by anyone else involved in the trial with the following exceptions: (1) data managers who work on the randomization and drug management system, (2) unblinded statistician(s) involved with the response adaptive randomization, and (3) the unblinded biostatistician who prepares reports for the IDMC. Information on the blind, or lack thereof, per domain will be described in the respective Domain-Specific Appendix.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>BEAT-Calci Wound Assessment Scale (BCWAS) - Baseline to Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>To determine whether addition of the intervention changes the sentinel ulcer from Baseline to Week 12 on the BEAT-Calci Wound Assessment Scale. This is an 8-point ordinal categorical scale of change since baseline, which will be used to determine each participant's outcome. The scale is described as:&#xD;
Complete epithelialisation of the sentinel ulcer&#xD;
&gt;50% reduction in sentinel ulcer surface area&#xD;
20-50% reduction in sentinel ulcer surface area&#xD;
0-20% reduction in sentinel ulcer surface area&#xD;
Any increase in sentinel ulcer surface area&#xD;
Development of new ulcers&#xD;
Amputation due to an ulcer&#xD;
All-cause death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BEAT-Calci Wound Assessment Scale - Baseline to Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>To determine whether addition of the intervention changes the sentinel ulcer from Baseline to Week 26 on the BEAT-Calci Wound Assessment Scale. This is an 8-point ordinal categorical scale of change since baseline, which will be used to determine each participant's outcome. The scale is described as:&#xD;
Complete epithelialisation of the sentinel ulcer&#xD;
&gt;50% reduction in sentinel ulcer surface area&#xD;
20-50% reduction in sentinel ulcer surface area&#xD;
0-20% reduction in sentinel ulcer surface area&#xD;
Any increase in sentinel ulcer surface area&#xD;
Development of new ulcers&#xD;
Amputation due to an ulcer&#xD;
All-cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of each of the individual components of the BCWAS, assessed at Weeks 4</measure>
    <time_frame>Week 4</time_frame>
    <description>To determine whether addition of the intervention changes the distribution of each of the individual components of the BEAT-Calci Wound Assessment Scale, assessed at Weeks 4&#xD;
Scale described as:&#xD;
Complete epithelialisation of the sentinel ulcer&#xD;
&gt;50% reduction in sentinel ulcer surface area&#xD;
20-50% reduction in sentinel ulcer surface area&#xD;
0-20% reduction in sentinel ulcer surface area&#xD;
Any increase in sentinel ulcer surface area&#xD;
Development of new ulcers&#xD;
Amputation due to an ulcer&#xD;
All-cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of each of the individual components of the BCWAS, assessed at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>To determine whether addition of the intervention changes the distribution of each of the individual components of the BEAT-Calci Wound Assessment Scale, assessed at Week 12&#xD;
Scale described as:&#xD;
Complete epithelialisation of the sentinel ulcer&#xD;
&gt;50% reduction in sentinel ulcer surface area&#xD;
20-50% reduction in sentinel ulcer surface area&#xD;
0-20% reduction in sentinel ulcer surface area&#xD;
Any increase in sentinel ulcer surface area&#xD;
Development of new ulcers&#xD;
Amputation due to an ulcer&#xD;
All-cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of each of the individual components of the BCWAS, assessed at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>To determine whether addition of the intervention changes the distribution of each of the individual components of the BEAT-Calci Wound Assessment Scale, assessed at Week 26.&#xD;
Scale described as:&#xD;
Complete epithelialisation of the sentinel ulcer&#xD;
&gt;50% reduction in sentinel ulcer surface area&#xD;
20-50% reduction in sentinel ulcer surface area&#xD;
0-20% reduction in sentinel ulcer surface area&#xD;
Any increase in sentinel ulcer surface area&#xD;
Development of new ulcers&#xD;
Amputation due to an ulcer&#xD;
All-cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bates-Jensen Wound Assessment Tool - from Baseline to Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>To determine whether addition of the intervention changes the severity of sentinel ulcer from Baseline, assessed at Week 4 using the Bates-Jensen Wound Assessment Tool</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bates-Jensen Wound Assessment Tool - from Baseline to Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>To determine whether addition of the intervention changes the severity of sentinel ulcer from Baseline, assessed at Week 12, using the Bates-Jensen Wound Assessment Tool</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bates-Jensen Wound Assessment Tool - from Baseline to Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>To determine whether addition of the intervention changes the severity of sentinel ulcer from Baseline, assessed at Week 26, using the Bates-Jensen Wound Assessment Tool</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sentinel ulcer surface area - from Baseline, assessed at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>To determine whether addition of the intervention changes the surface area of sentinel ulcer from Baseline, assessed at Week 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sentinel ulcer surface area - from Baseline, assessed at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>To determine whether addition of the intervention changes the surface area of sentinel ulcer from Baseline, assessed at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sentinel ulcer surface area - from Baseline, assessed at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>To determine whether addition of the intervention changes the surface area of sentinel ulcer from Baseline, assessed at Week 26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All ulcers total surface area - from Baseline, assessed at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>To determine whether addition of the intervention changes the total surface area of all ulcers (not only the sentinel ulcer) from Baseline, assessed at Week 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All ulcers total surface area - from Baseline, assessed at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>To determine whether addition of the intervention changes the total surface area of all ulcers (not only the sentinel ulcer) from Baseline, assessed at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All ulcers total surface area - from Baseline, assessed at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>To determine whether addition of the intervention changes the total surface area of all ulcers (not only the sentinel ulcer) from Baseline, assessed at Week 26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change over time of self-reported pain</measure>
    <time_frame>Week 26</time_frame>
    <description>To determine whether addition of the intervention changes self-reported pain over time, assessed using the 0-to-10 Numerical Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported pain at week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>To determine whether addition of the intervention changes self-reported pain use at week 12 assessed using the 0-to-10 Numerical Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change over time of analgesic use</measure>
    <time_frame>Week 26</time_frame>
    <description>To determine whether addition of the intervention changes analgesic use over time, as measured by cumulative weighted analgesia dose from baseline to week 26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic use week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>To determine whether addition of the intervention changes analgesic use over time, as measured by cumulative weighted analgesia dose from baseline to week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite self-reported pain and analgesic use over time</measure>
    <time_frame>Week 26</time_frame>
    <description>To determine whether addition of the intervention changes the composite outcome of self-reported pain (assessed using the 0-to-10 Numerical Rating Scale) and analgesic use over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite self-reported pain and analgesic use at week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>To determine whether addition of the intervention changes the composite outcome of self-reported pain (assessed using the 0-to-10 Numerical Rating Scale) and analgesic use at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in self-reported quality of life from Baseline to Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>To determine whether addition of the intervention changes self-reported quality of life from Baseline, assessed at Week 4, using the EuroQoL EQ-5D-5L instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in self-reported quality of life from Baseline to Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>To determine whether addition of the intervention changes self-reported quality of life from Baseline, assessed at Week 12, using the EuroQoL EQ-5D-5L instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in self-reported quality of life from Baseline to Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>To determine whether addition of the intervention changes self-reported quality of life from Baseline, assessed at Week 26 using the EuroQoL EQ-5D-5L instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first calciphylaxis-attributable infection from Baseline to Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>Time in days to first calciphylaxis-attributable infection within 26 weeks post-randomisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause hospitalisation days</measure>
    <time_frame>Weeks 0-26</time_frame>
    <description>Count of all cause hospitalisation days (excluding day admissions for dialysis treatment within 26 weeks post-randomisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Incidence of mortality, as derived from hospital reports, within 5-years post-randomisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney Transplantation</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Incidence of kidney transplantation, as derived from hospital reports, within 5-years post-randomisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calciphylaxis recurrence</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Incidence of calciphylaxis recurrence as derived from hospital reports, within 5-years post-randomisation</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Calciphylaxis</condition>
  <arm_group>
    <arm_group_label>Placebo (Double-Blind Period)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Vitamin K1 Placebo Magnesium Citrate Placebo Sodium Thiosulphate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin K1 (Double-Blind Period)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose: 10mg Vitamin K1 capsules, administered 3 times per week following the subject's hemodialysis session.&#xD;
Placebo Magnesium Citrate&#xD;
Placebo Sodium Thiosulphate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnesium Citrate (Double-Blind Period)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose: 150mg Magnesium Citrate tablets, administered 3 times per day. On dialysis days, administration of the middle daily dose should occur following the subject's hemodialysis session.&#xD;
Placebo Vitamin K1&#xD;
Placebo Sodium Thiosulphate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Thiosulfate (Double-Blind Period)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose: 25g Sodium Thiosulfate injection, administered intravenously 3 times per week, during the subject's last hour of hemodialysis.&#xD;
Placebo Vitamin K1&#xD;
Placebo Magnesium Citrate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Flux Hemodialysis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hemodialysis using a high flux dialyser</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium Cut-off Hemodialysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hemodialysis using a medium cut-off dialyser</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin K1</intervention_name>
    <description>Vitamin K1 capsule (10mg) to be administered 3 times per week following the subject's hemodialysis session.</description>
    <arm_group_label>Vitamin K1 (Double-Blind Period)</arm_group_label>
    <other_name>Phytonadione</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium citrate</intervention_name>
    <description>Magnesium Citrate tablet (150mg) to be administered 3 times per per day. On dialysis days, administration of the middle daily dose should occur following the subject's hemodialysis session.</description>
    <arm_group_label>Magnesium Citrate (Double-Blind Period)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Thiosulfate</intervention_name>
    <description>Sodium Thiosulfate injection (25g/100ml) to be administered intravenously 3 times per week, during the subject's last hour of hemodialysis.</description>
    <arm_group_label>Sodium Thiosulfate (Double-Blind Period)</arm_group_label>
    <other_name>Intravenous Sodium Thiosulfate Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High Flux Dialyser</intervention_name>
    <description>Hemodialysis using a high flux dialyser.</description>
    <arm_group_label>High Flux Hemodialysis</arm_group_label>
    <other_name>High Flux Hemodialysis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medium Cut-off Dialyser</intervention_name>
    <description>Hemodialysis using a medium cut-off dialyser.</description>
    <arm_group_label>Medium Cut-off Hemodialysis</arm_group_label>
    <other_name>Medium Cut-off Hemodialysis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo injection (normal saline)</intervention_name>
    <description>Placebo to be administered intravenously 3 times per week, during the subject's last hour of hemodialysis.</description>
    <arm_group_label>Magnesium Citrate (Double-Blind Period)</arm_group_label>
    <arm_group_label>Placebo (Double-Blind Period)</arm_group_label>
    <arm_group_label>Vitamin K1 (Double-Blind Period)</arm_group_label>
    <other_name>0.9% sodium chloride solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsule (Vitamin K1)</intervention_name>
    <description>Placebo to be administered 3 times per week following the subject's hemodialysis session.</description>
    <arm_group_label>Magnesium Citrate (Double-Blind Period)</arm_group_label>
    <arm_group_label>Placebo (Double-Blind Period)</arm_group_label>
    <arm_group_label>Sodium Thiosulfate (Double-Blind Period)</arm_group_label>
    <other_name>Matching placebo capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablet (Magnesium citrate)</intervention_name>
    <description>Placebo to be administered 3 times per day. On dialysis days, administration of the middle daily dose should occur following the subject's hemodialysis session.</description>
    <arm_group_label>Placebo (Double-Blind Period)</arm_group_label>
    <arm_group_label>Sodium Thiosulfate (Double-Blind Period)</arm_group_label>
    <arm_group_label>Vitamin K1 (Double-Blind Period)</arm_group_label>
    <other_name>Matching placebo tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Currently receiving haemodialysis, or peritoneal dialysis that can be converted to&#xD;
             haemodialysis, with planned ongoing haemodialysis a minimum of three times per week&#xD;
             for at least the duration of the protocolised calciphylaxis treatments within this&#xD;
             trial&#xD;
&#xD;
          2. Have a new calciphylaxis ulcer present for less than 10 weeks&#xD;
&#xD;
          3. Age â‰¥ 18 years&#xD;
&#xD;
          4. Eligible for randomisation in at least one recruiting domain&#xD;
&#xD;
          5. The participant and treating physician are willing and able to perform trial&#xD;
             procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Nil&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meg Jardine</last_name>
    <role>Study Chair</role>
    <affiliation>University of Sydney</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arlen Wilcox</last_name>
    <phone>9562 5203</phone>
    <email>arlen.wilcox@sydney.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meg Jardine</last_name>
    <phone>9562 5000</phone>
    <email>meg.jardine@sydney.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Auburn Hospital</name>
      <address>
        <city>Auburn</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Grahame Elder</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blacktown Hospital</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Grahame Elder</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Concord Repatriation General Hospital</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angus Ritchie</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St George Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brendan Smyth</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angela Makris</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sradha Kotwal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Grahame Elder</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunshine Coast Hospital and Health Service</name>
      <address>
        <city>Birtinya</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rathika Krishnasamy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmel Hawley</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bundaberg Base Hospital</name>
      <address>
        <city>Bundaberg</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clyson Mutatiri</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cairns Hospital</name>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine Wilkinson</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Townsville Hospital</name>
      <address>
        <city>Townsville</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vikas Srivastava</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Ruderman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunshine Hospital (Western Health)</name>
      <address>
        <city>St Albans</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eugenia Pedagogos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Armadale Hospital (East Metropolitan Health Services)</name>
      <address>
        <city>Armadale</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hemant Kulkarni</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital (East Metropolitan Health Services)</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hemant Kulkarni</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital (Auckland DHB)</name>
      <address>
        <city>Grafton</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tze Goh</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital (Waikato DHB)</name>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kaniyan Rabindrinath</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Shore Hospital (Waitemata DHB)</name>
      <address>
        <city>Takapuna</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Janak de Zoysa</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 9, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calciphylaxis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Vitamin K 1</mesh_term>
    <mesh_term>Sodium thiosulfate</mesh_term>
    <mesh_term>Magnesium citrate</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Sodium Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Trial data will be disseminated in the form of a publication to a relevant clinical journal and presentation at appropriate scientific conferences.&#xD;
Individual participant data that underlie the results reported, after de-identification (text, tables, figures, and appendices), may be shared with Investigators whose proposed use of the data has been approved by a review committee identified for this purpose.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>To be confirmed</ipd_time_frame>
    <ipd_access_criteria>No data should be released that would compromise the trial, unless specifically for safety reasons.&#xD;
There must be a strong scientific or other legitimate rationale for the data to be used for the requested purpose.&#xD;
Investigators should have a period of exclusivity in which to pursue their aims with the data, before key trial data are made available to other researchers.&#xD;
Adequate resources must be available in order to comply with the request, and the scientific aims of the study must justify the use of such resources.&#xD;
Data release complies with the relevant regulations from all relevant countries.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

